Latest Breaking News On - Camilla chong - Page 1 : comparemela.com

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

JENA, Germany, May 21, 2024 InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American.

San diegoUnited statesInflarx gmbRegina lutzCamilla chongLaurie doyleJan medinaKatja arnoldGlobenewswire incInflarx pharmaceuticals incInflarx commitment programDrug administrationAmerican thoracic societyInternational conferenceEuropean medicines agencyMc services

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg .

United statesSan franciscoKatja arnoldCamilla chongLaurie doyleRegina lutzMc servicesExchange commissionInflarx pharmaceuticals incDrug administrationEuropean medicines agencyChief medical officerInflarx pharmaceuticalsAnn arborEmergency use authorizationMarketing authorization application

InflaRx N V (IFRX) Reports Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study of INF904

InflaRx N V (IFRX) Reports Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study of INF904
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Camilla chongChief medical officer

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Camilla chongKristen dowdEuropean medicines agencyIndustry news

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesCamilla chongKatja arnoldRegina lutzLaurie doyleExchange commissionEuropean committee for medicinal products humanInflarx pharmaceuticals incEuropean medicines agencyMc servicesDrug administrationChief medical officerFast trackOrphan drugEmergency use authorizationMarketing authorization application